Shanghai Kehua Bio-engineering Co., Ltd. China's leading In Vitro Diagnostic (IVD) company has achieved a significant milestone by becoming the first Chinese company to obtain EU Class D In Vitro Diagnostic Regulation (IVDR) certification for rapid tests.
As parents stock up their medicine cabinets for cold and flu season, DrKids, the leader in innovative, effective medicines and supplements, has introduced the first ever acetaminophen gummy bite.
Home-use medical device manufacturer Hexainnoheal has been gaining recognition for its pain therapy products. Hexainnoheal manufactures healthcare devices using Low Level Lasers and LED lighting. Its primary product line-up includes PainQ for pain management and CobiQ for rhinitis management. Hexainnoheal also focuses on developing a new product called Flexible PainQ.
Stryker (NYSE: SYK), one of the world's leading medical technology companies, continues its year of milestones celebration with the 10th anniversary of the Triathlon Tritanium baseplate.
Waters Corporation (NYSE:WAT) introduces the DynaPro™ ZetaStar™ instrument from its Wyatt Technology™ portfolio for nanoparticle analysis.
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases has launched an on-site dialysis program with Sarah Bush Lincoln, a regional health system in Mattoon, IL.
Andersen Sterilizers and its sister company, contract sterilization specialist Andersen Scientific, were awarded the very first master file in the FDA's 510(k) Ethylene Oxide (EO) Sterility Change Master File Pilot Program.
In a groundbreaking development, India-based company Voxelgrids has launched an advanced and affordable MRI scanner with the potential to revolutionize healthcare accessibility not only in India but also worldwide.
By order of a U.S. bankruptcy court, Tiger Group and Liquidity Services on Aug. 10 will auction OncoSec Medical Inc.'s former immunotherapy laboratory and R&D facility in San Diego.
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved the first at-home oral pill, zuranolone, which will be sold under the brand named Zurzuvae, for treating perinatal or postpartum depression (PPD) – a condition one in eight birthing women experience.